Navigation Links
TGen, Virginia G. Piper Cancer Center scientist heads lung cancer consortium
Date:6/8/2011

SCOTTSDALE, Ariz. June 8, 2011 Dr. Glen Weiss, who holds joint appointments at the Translational Genomics Research Institute (TGen) and at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, is the new Chief Medical Officer of an international lung cancer research consortium.

In this new position, Dr. Weiss heads the Cancer Research and Biostatistics-Clinical Trials Consortium (CRAB-CTC), a Seattle-based cooperative research network, created by a group of preeminent lung cancer investigators. It represents more than 10 institutes worldwide dedicated to funding and facilitating clinical trials, thereby providing lung cancer patients with newly developed therapeutics as quickly as possible.

"Our Consortium's explicit mission is to organize and accelerate the clinical development of new agents for the treatment of patients with lung cancer," said Dr. Weiss, an Assistant Professor of TGen's Cancer and Cell Biology Division. He also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

CRAB-CTC members include laboratory and clinical researchers in the U.S., Canada and China who share a passion for bringing new scientific advances to patients with lung cancer as rapidly as possible.

"Our Consortium provides a well-coordinated effort dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with lung cancer," said Dr. Weiss.

Unlike similar research consortiums, CRAB-CTC is not affiliated or funded by government, but works directly with pharmaceutical firms to advance their compounds.

"CRAB's mission is to help conquer cancer. The network provided by the CRAB-CTC enables research oncologists to design and conduct innovative studies more
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
2. Virginia Tech mechanical engineers win measurement science best paper award
3. Virginia Tech announces football helmet ratings for reducing concussion risk
4. Young scientist at Virginia Commonwealth University wins Avanti prize
5. Virginia Tech forest researcher awarded NSF early career grant
6. Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients
7. Virginia Tech shares in grant to study effects of climate change on southern pine forests
8. Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
9. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
10. USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry
11. Virginia Tech studies impact of Gulf oil spill on plovers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... of years ago are recorded at daily rate in ... X-ray microscope has revealed growth bands in plankton shells ... The results could allow scientists to chart short ... years ago. Plankton shells show features like tree ...
... available in German . ... loss of eye lashes and eye brows, susceptibility to infection ... lengthy. Many cancer patients suffer from the intense effects that ... subcutaneously or administered intravenously to halt the growth of tumors ...
... salvia magnesium acetate, is a phenolic acid compound ... of caffeic acid. Salvianolic acid B exerts strong ... improves energy metabolism against cerebral ischemia-reperfusion injuries. Dr. ... Xiangya Hospital, Central South University, China found that ...
Cached Biology News:Reading ancient climate from plankton shells 2Nano-dwarves turn tumor assassins 2Nano-dwarves turn tumor assassins 3
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Cynosure, Inc. (NASDAQ: CYNO ) today announced financial ... Revenues for the first quarter of 2011 increased 16 percent ... 2010.   Net loss for the first quarter of 2011 was ... a net loss of $2.8 million, or $0.22 per basic and ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... The net income for the first quarter ended ... loss of $14.1 million during the same period in 2010. ... was related primarily to the $34.2 million in collaboration revenue ...
... VIVUS, Inc. (Nasdaq: VVUS ), a ... products, today reported its financial results for the first quarter ended ... quarter ended March 31, 2011, VIVUS reported a net loss of ... loss of $18.8 million or $0.23 per share for the first ...
Cached Biology Technology:Cynosure Reports Financial Results for the First Quarter of 2011 2Cynosure Reports Financial Results for the First Quarter of 2011 3Cynosure Reports Financial Results for the First Quarter of 2011 4Cynosure Reports Financial Results for the First Quarter of 2011 5Cynosure Reports Financial Results for the First Quarter of 2011 6MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
... from 2 mM sodium phosphate buffer, pH ... D is a major lysosomal aspartyl protease ... kDa proenzyme. Overexpression of cathepsin D in ... risk of relapse and metastasis. Cathepsin D ...
Acetate Plate Sealers 100/Box...
...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Biology Products: